Unnamed: 0,title,date,stock,sentiment
926921.0,"Wells Fargo Maintains Equal-Weight on NuVasive, Raises Price Target to $63",2020-06-05 10:32:00-04:00,NUVA,positive
926922.0,"The Daily Biotech Pulse: Cumberland's Positive Anti-Bacterial Readout, FDA Nods For Bristol-Myers, Astellas",2020-05-27 07:25:00-04:00,NUVA,positive
926923.0,Shares of several healthcare companies are trading higher in sympathy with the overall market as optimism around a coronavirus vaccine increased following news from Moderna.,2020-05-18 10:23:00-04:00,NUVA,positive
926924.0,Shares of several healthcare companies are trading higher after US unemployment figures came in below consensus estimates. Equities have been strong this week amid a rebound in oil prices and some US states easing lockdown restrictions.,2020-05-08 10:56:00-04:00,NUVA,positive
926925.0,"Canaccord Genuity Maintains Buy on NuVasive, Lowers Price Target to $64",2020-05-07 13:54:00-04:00,NUVA,negative
926926.0,"Citigroup Maintains Neutral on NuVasive, Raises Price Target to $58",2020-05-07 12:48:00-04:00,NUVA,neutral
926927.0,"UBS Maintains Sell on NuVasive, Lowers Price Target to $55",2020-05-07 12:32:00-04:00,NUVA,negative
926928.0,NuVasive Withdraws Its FY20 Guidance Due To Coronavirus,2020-05-06 16:31:00-04:00,NUVA,neutral
926929.0,"NuVasive Q1 EPS $0.480 Beats $0.430 Estimate, Sales $259.900M Miss $273.880M Estimate",2020-05-06 16:30:00-04:00,NUVA,negative
926930.0,"The Daily Biotech Pulse: FDA Nod For AstraZeneca, AbbVie-Allergan Deal Clears Antitrust Hurdle",2020-05-06 08:42:00-04:00,NUVA,positive
926931.0,"JP Morgan Maintains Neutral on NuVasive, Lowers Price Target to $60",2020-05-04 09:42:00-04:00,NUVA,positive
926932.0,The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace,2020-05-03 08:45:00-04:00,NUVA,neutral
926933.0,Shares of several healthcare companies are trading higher amid optimistic coronavirus outlook following positive drug data from Gilead. This has raised hopes of a sooner return to spending and economic activity.,2020-04-17 10:04:00-04:00,NUVA,positive
926934.0,NuVasive Withdraws FY20 Guidance,2020-04-14 16:03:00-04:00,NUVA,neutral
926935.0,NuVasive Sees Q1 Sales $259M-$261M vs $282M Estimate,2020-04-14 16:03:00-04:00,NUVA,neutral
926936.0,NuVasive Outlines Expense Control Measures Amid Coronavirus Pandemic,2020-04-14 16:02:00-04:00,NUVA,neutral
926937.0,"Benzinga's Top Upgrades, Downgrades For April 8, 2020",2020-04-08 09:35:00-04:00,NUVA,positive
926938.0,NuVasive shares are trading higher after Baird upgraded the stock from Neutral to Outperform.,2020-04-08 08:44:00-04:00,NUVA,positive
926939.0,"Wells Fargo Maintains Equal-Weight on NuVasive, Lowers Price Target to $56",2020-04-08 08:25:00-04:00,NUVA,positive
926940.0,10 Biggest Price Target Changes For Wednesday,2020-04-08 08:22:00-04:00,NUVA,neutral
926941.0,"Baird Upgrades NuVasive to Outperform, Lowers Price Target to $66",2020-04-08 06:18:00-04:00,NUVA,negative
926942.0,Shares of several healthcare companies are trading higher amid optimism that coronavirus cases in Asia are potentially easing. Global slowing cases could raise hopes of a sooner return to spending and economic activity. Several companies in the sector may also be benefiting from increased demand for therapies and medical supplies amid the coronavirus pandemic.,2020-04-07 07:48:00-04:00,NUVA,positive
926943.0,"Morgan Stanley Maintains Equal-Weight on NuVasive, Lowers Price Target to $63",2020-03-27 09:58:00-04:00,NUVA,negative
926944.0,"Citigroup Maintains Neutral on NuVasive, Lowers Price Target to $55",2020-03-27 09:00:00-04:00,NUVA,negative
926945.0,"The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latestage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection",2020-03-19 07:37:00-04:00,NUVA,neutral
926946.0,"The Daily Biotech Pulse: AbbVie, Allergan Agree On Divestments, Obalon Stops Obesity Balloon Sale, COVID-19 Updates",2020-03-18 07:36:00-04:00,NUVA,positive
926947.0,"The Daily Biotech Pulse: Setback For DBV In Peanut Allergy Patch Review, Roche Starts Coronavirus Test Shipment, Regeneron Aims For 'Cocktail' COVID-19 Treatment",2020-03-17 08:48:00-04:00,NUVA,neutral
926948.0,Stocks That Hit 52-Week Lows On Friday,2020-03-13 11:13:00-04:00,NUVA,negative
926949.0,"The Daily Biotech Pulse: Roche Obtains FDA Emergency Use Authorization For COVID-19 Test, Chembio Appoints New CEO, Inovio Slumps On Earnings",2020-03-13 07:52:00-04:00,NUVA,negative
926950.0,Stocks That Hit 52-Week Lows On Thursday,2020-03-12 12:10:00-04:00,NUVA,negative
926951.0,"The Daily Biotech Pulse: AstraZeneca Faces Setback In Ovarian Cancer Study, Mallinckrodt To Explore COVID-19 Treatment, Imara IPO",2020-03-12 07:37:00-04:00,NUVA,negative
926952.0,Stocks That Hit 52-Week Lows On Wednesday,2020-03-11 11:41:00-04:00,NUVA,negative
926953.0,"Credit Suisse Maintains Outperform on NuVasive, Lowers Price Target to $86",2020-03-06 10:34:00-05:00,NUVA,positive
926954.0,"Benzinga's Top Upgrades, Downgrades For March 5, 2020",2020-03-05 10:05:00-05:00,NUVA,positive
926955.0,"Citigroup Initiates Coverage On NuVasive with Neutral Rating, Announces $68 Price Target",2020-03-05 04:58:00-05:00,NUVA,neutral
926956.0,"Cantor Fitzgerald Maintains Neutral on NuVasive, Raises Price Target to $85",2020-02-21 06:24:00-05:00,NUVA,neutral
926957.0,"NuVasive Sees FY20 Revenue Growth 4-6%, EPS $2.55-$2.65 Vs. $2.60 Est.",2020-02-20 16:06:00-05:00,NUVA,positive
926958.0,"NuVasive Q4 EPS $0.73 Beats $0.64 Estimate, Sales $310.4M Beat $304.78M Estimate",2020-02-20 16:04:00-05:00,NUVA,neutral
926959.0,"The Daily Biotech Pulse: Heron Pain Drug Review Extended, Disappointment For Teva In Tourette Syndrome Study",2020-02-20 07:06:00-05:00,NUVA,negative
926960.0,"Earnings Scheduled For February 20, 2020",2020-02-20 04:17:00-05:00,NUVA,neutral
926961.0,"The Week Ahead In Biotech: Baudax Bio, Merck, Esperion Await FDA Decisions",2020-02-16 15:03:00-05:00,NUVA,positive
926962.0,"The Daily Biotech Pulse: Osmotica Soars On Insider Buys, Ultragenyx's Partnered Rare Disease Drug Moves Into Clinics",2020-01-16 07:22:00-05:00,NUVA,neutral
926963.0,"The Daily Biotech Pulse: Nektar Withdraws Opioid Pain Drug NDA, Galapagos Takes Stake In Fibrocor, Integra Lifesciences Lowers Q4 Guidance",2020-01-15 08:22:00-05:00,NUVA,negative
926964.0,"Baird Maintains Neutral on NuVasive, Raises Price Target to $82",2020-01-14 09:20:00-05:00,NUVA,neutral
926965.0,"The Daily Biotech Pulse: PhaseBio To Buy Hypertension Asset, Stemline Falls On Q4 Pre-Announcement, FDA Panel To Review Nektar's Opioid Drug",2020-01-14 07:55:00-05:00,NUVA,positive
926966.0,NuVasive Sees FY2019 Sales $1.17B vs $1.16B Est,2020-01-13 08:48:00-05:00,NUVA,neutral
926967.0,NuVasive Sees Q4 Sales $310M vs $304.32M Est,2020-01-13 08:47:00-05:00,NUVA,neutral
926968.0,Stocks That Hit 52-Week Highs On Friday,2020-01-10 12:18:00-05:00,NUVA,neutral
926969.0,"The Daily Biotech Pulse: Positive Data Readouts To Spur Aclaris, Moderna And Ultragenyx",2020-01-10 07:13:00-05:00,NUVA,positive
926970.0,Stocks That Hit 52-Week Highs On Thursday,2020-01-09 15:15:00-05:00,NUVA,neutral
926971.0,"The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, DBV Announces Positive Peanut Allergy Study Findings, Applied Genetic Soars On Trial Results",2020-01-09 08:39:00-05:00,NUVA,positive
926972.0,"NuVasive Is 'A Stock To Watch For In 2020,' SunTrust Says In Bullish Initiation",2020-01-08 13:28:00-05:00,NUVA,neutral
926973.0,"Benzinga's Top Upgrades, Downgrades For January 8, 2020",2020-01-08 10:56:00-05:00,NUVA,positive
926974.0,"Credit Suisse Maintains Outperform on NuVasive, Raises Price Target to $87",2020-01-08 10:50:00-05:00,NUVA,positive
926975.0,"SunTrust Robinson Humphrey Initiates Coverage On NuVasive with Buy Rating, Announces $93 Price Target",2020-01-08 09:51:00-05:00,NUVA,neutral
926976.0,"The Daily Biotech Pulse: Verastem In-Licenses Chughai's Tumor Drug, Midatech Surges On Positive Study Results",2020-01-08 08:12:00-05:00,NUVA,positive
926977.0,"The Daily Biotech Pulse: Acorda Surges As Point72 Hikes Stake, Novan Sinks On Failed Study, Illumina-Pac Bio Terminate Merger",2020-01-03 07:55:00-05:00,NUVA,negative
926978.0,NuVasive Appoints Matthew K. Harbaugh CFO,2020-01-02 16:04:00-05:00,NUVA,neutral
926979.0,"The Daily Biotech Pulse: Qiagen Opts To Stay Solo Following Strategic Review, Spectrum Slumps On Negative Data, Microbot Medical To Offer Shares",2019-12-26 07:55:00-05:00,NUVA,negative
926980.0,"The Daily Biotech Pulse: NewLink Genetics Licenses Ovarian Cancer Dug, Correvio Awaits FDA Verdict",2019-12-24 07:24:00-05:00,NUVA,negative
926981.0,Stocks That Hit 52-Week Highs On Monday,2019-12-23 10:20:00-05:00,NUVA,neutral
926982.0,"The Daily Biotech Pulse: Positive Adcom Verdict For Merck, Homology Medicine Slips On Mixed Gene Therapy Efficacy Data",2019-12-18 07:23:00-05:00,NUVA,positive
926983.0,Stocks That Hit 52-Week Highs On Tuesday,2019-12-17 11:19:00-05:00,NUVA,neutral
926984.0,"Morgan Stanley Maintains Equal-Weight on NuVasive, Raises Price Target to $82",2019-12-17 09:18:00-05:00,NUVA,neutral
926985.0,"The Daily Biotech Pulse: Roche Gets US Antitrust Clearance For Spark Purchase, An Orphan Drug Designation For Prevail, Dynavax Names CEO",2019-12-17 07:56:00-05:00,NUVA,positive
926986.0,"SVB Leerink Earlier Maintained Outperform on NuVasive, Raised Price Target to $92",2019-12-13 12:29:00-05:00,NUVA,neutral
926987.0,Stocks That Hit 52-Week Highs On Friday,2019-12-13 11:19:00-05:00,NUVA,neutral
926988.0,Stocks That Hit 52-Week Highs On Friday,2019-12-06 10:33:00-05:00,NUVA,neutral
926989.0,"The Daily Biotech Pulse: Cassava Gains On Alzheimer's Presentation, Bristol-Myers Hikes Dividend",2019-12-06 07:39:00-05:00,NUVA,positive
926990.0,NuVasive Reports Receives FDA Clearance For Expanded Multi-Level Use Of CoRoent Small Interlock System For Cervical Spine,2019-11-21 08:38:00-05:00,NUVA,neutral
926991.0,Stocks That Hit 52-Week Highs On Monday,2019-11-18 11:01:00-05:00,NUVA,neutral
926992.0,NuVasive Raised FY19 EPS Guidance From $2.25-$2.35 To $2.35-$2.40 vs $2.32 Est.,2019-10-30 17:29:00-04:00,NUVA,neutral
926993.0,NuVasive Raises FY19 Sales Guidance From $1.14B-$1.16B To $1.16B vs $1.16B Est.,2019-10-30 17:27:00-04:00,NUVA,neutral
926994.0,"NuVasive Q3 EPS $0.59 Beats $0.53 Estimate, Sales $290.8M Beat $283.76M Estimate",2019-10-30 17:21:00-04:00,NUVA,neutral
926995.0,"UBS Maintains Sell on NuVasive, Raises Price Target to $55",2019-09-10 07:50:00-04:00,NUVA,neutral
926996.0,"UPDATE: UBS Maintains Sell On NuVasive, Raises Target To $55 As Firm Notes 'Despite the better recent performance, we remain Sell rated on the shares but are increasing our PT to account for NUVA's momentum and upcoming product launches'",2019-09-09 11:19:00-04:00,NUVA,neutral
926997.0,"UBS Maintains Sell on NuVasive, Raises Price Target to $55",2019-09-09 07:31:00-04:00,NUVA,neutral
926998.0,NuVasive Highlights Launch Of Porous Titanium Implant,2019-09-05 08:39:00-04:00,NUVA,neutral
926999.0,Alphatec Announces Favorable Judgment In NuVasive v. Miles Lawsuit,2019-08-27 09:02:00-04:00,NUVA,positive
927000.0,"BMO Capital Maintains Market Perform on NuVasive, Raises Price Target to $68",2019-08-09 08:47:00-04:00,NUVA,neutral
927001.0,NuVasive Presents Long-Term Strategy and Financial Outlook at 2019 Investor Day,2019-08-08 06:14:00-04:00,NUVA,neutral
927002.0,88 Biggest Movers From Yesterday,2019-08-01 05:41:00-04:00,NUVA,neutral
927003.0,71 Stocks Moving In Wednesday's Mid-Day Session,2019-07-31 12:32:00-04:00,NUVA,neutral
927004.0,NuVasive shares are trading higher after the company reported better-than-expected Q2 EPS and sales results.,2019-07-31 10:02:00-04:00,NUVA,positive
927005.0,42 Stocks Moving In Wednesday's Pre-Market Session,2019-07-31 08:17:00-04:00,NUVA,neutral
927006.0,"Morgan Stanley Maintains Equal-Weight on NuVasive, Raises Price Target to $67",2019-07-31 07:54:00-04:00,NUVA,neutral
927007.0,28 Healthcare Stocks Moving In Tuesday's After-Market Session,2019-07-31 04:01:00-04:00,NUVA,neutral
927008.0,8 Stocks Moving In Tuesday's After-Hours Session,2019-07-30 17:12:00-04:00,NUVA,neutral
927009.0,NuVasive shares are trading higher after the company reported better-than-expected Q2 EPS and sales results.,2019-07-30 16:30:00-04:00,NUVA,positive
927010.0,"NuVasive Q2 Adj. EPS $0.63 Beats $0.56 Estimate, Sales $292.1M Beat $290.59M Estimate",2019-07-30 16:26:00-04:00,NUVA,neutral
927011.0,"Benzinga's Top Upgrades, Downgrades For July 29, 2019",2019-07-29 09:55:00-04:00,NUVA,positive
927012.0,"Baird Downgrades NuVasive to Neutral, Announces $66 Price Target",2019-07-29 07:38:00-04:00,NUVA,neutral
927013.0,NuVasive Launches Pulse Integrated Technology Platform To Enable Better Spine Surgery,2019-07-10 08:46:00-04:00,NUVA,positive
927014.0,NuVasive Reports SpineTRACK Registry Successfully Met 2018 Medicare Reporting Requirements For Merit-Based Incentive Payment System,2019-05-30 08:33:00-04:00,NUVA,positive
927015.0,"NuVasive Reaffirms FY19 Adj. EPS Guidance Of $2.20-$2.30 vs $2.25 Est., Sales Guidance Of $1.14B-$1.16B vs $1.15B Est.",2019-05-01 16:05:00-04:00,NUVA,neutral
927016.0,"NuVasive Q1 Adj. EPS $0.53 Beats $0.41 Estimate, Sales $274.8M Beat $269.48M Estimate",2019-05-01 16:04:00-04:00,NUVA,neutral
927017.0,A Preview Of NuVasive's Q1 Earnings,2019-05-01 11:53:00-04:00,NUVA,neutral
927018.0,"Shares of several healthcare stocks are trading higher in a potential rebound from last week's selloff. In an upgrade of HCA Healthcare, Raymond James analysts noted the selloff was 'based on legislation that has almost no chance of passing'",2019-04-23 11:52:00-04:00,NUVA,positive
927019.0,NuVasive Highlights Publication Of Study Results Of Its PEEK Implant In A Medical Journal,2019-04-22 08:35:00-04:00,NUVA,neutral
927020.0,Shares of several medical device companies are trading lower with the healthcare sector. Healthcare has seen weakness recently due to concerns over the future of the Affordable Act under Trump and healthcare policy uncertainty ahead of the 2020 election.,2019-04-17 12:45:00-04:00,NUVA,negative
927021.0,56 Biggest Movers From Yesterday,2019-03-13 06:04:00-04:00,NUVA,neutral
927022.0,42 Stocks Moving In Tuesday's Mid-Day Session,2019-03-12 14:06:00-04:00,NUVA,neutral
927023.0,"NuVasive Sees FY19 Adj. EPS $2.20-$2.30 vs $2.47 Estimate, Sales $1.14B-$1.16B vs $1.17B Est.",2019-02-20 16:03:00-05:00,NUVA,neutral
927024.0,"NuVasive Q4 EPS $0.69 Beats $0.64 Estimate, Sales $288.3M Miss $291.94M Estimate",2019-02-20 16:02:00-05:00,NUVA,negative
927025.0,"Earnings Scheduled For February 20, 2019",2019-02-20 04:04:00-05:00,NUVA,neutral
927026.0,"NuVasive Reports Its Proprietary Magnetic Implant System Received FDA 510(k) Clearance, CE Mark Approval, Will Be Used In First-Of-Kind All-Internal Bone Transport System",2019-02-19 08:32:00-05:00,NUVA,positive
927027.0,"Jefferies Downgrades NuVasive, Says M&A Unlikely To Materialize",2019-02-12 10:21:00-05:00,NUVA,neutral
927028.0,"Benzinga's Top Upgrades, Downgrades For February 12, 2019",2019-02-12 09:05:00-05:00,NUVA,positive
927029.0,Jefferies Downgrades NuVasive to Hold,2019-02-12 06:44:00-05:00,NUVA,neutral
927030.0,54 Biggest Movers From Yesterday,2019-02-12 04:44:00-05:00,NUVA,neutral
927031.0,"Benzinga Pro's Top 10 Most-Searched Tickers For Afternoon Of Mon., Feb. 11, 2019",2019-02-11 15:57:00-05:00,NUVA,positive
927032.0,35 Stocks Moving In Monday's Mid-Day Session,2019-02-11 12:27:00-05:00,NUVA,neutral
927033.0,Mid-Day Market Update: Crude Oil Down Over 2%; NuVasive Shares Spike Higher,2019-02-11 12:01:00-05:00,NUVA,negative
927034.0,Mid-Morning Market Update: Markets Edge Higher; Restaurant Brands Beats Q4 Estimates,2019-02-11 10:10:00-05:00,NUVA,neutral
927035.0,"Benzinga Pro's Top 10 Most-Searched Tickers For Morning Of Monday, February 11, 2019",2019-02-11 09:44:00-05:00,NUVA,positive
927036.0,NuVasive shares are trading higher following media reports that Smith & Nephew is in talks to acquire NuVassive for over $3B.,2019-02-11 08:50:00-05:00,NUVA,positive
927037.0,26 Stocks Moving In Monday's Pre-Market Session,2019-02-11 07:38:00-05:00,NUVA,neutral
927038.0,A Peek Into The Markets: US Stock Futures Signal Higher Start On Wall Street,2019-02-11 07:00:00-05:00,NUVA,neutral
927039.0,"8 Stocks To Watch For February 11, 2019",2019-02-11 04:24:00-05:00,NUVA,neutral
927040.0,NuVasive shares are trading higher after a Financial Times report surfaced that detailed Smith & Nephew is in talks to buy NuVasive for over $3 billion.,2019-02-08 16:28:00-05:00,NUVA,positive
927041.0,NuVasive Shares Spike 28% Just Ahead Of Close Amid FT Report 'Smith & Nephew in talks to buy NuVasive for over $3bn',2019-02-08 16:22:00-05:00,NUVA,positive
927042.0,Needham Downgrades NuVasive to Hold,2019-02-08 07:19:00-05:00,NUVA,neutral
927043.0,"The Daily Biotech Pulse: BioMarin Trims Outlook, MediciNova Enrolls First Patient In Brian Cancer Drug Study",2019-01-09 07:39:00-05:00,NUVA,negative
927044.0,"Stocks Which Set New 52-Week Low Yesterday, Mon., Jan. 7, 2019",2019-01-08 11:04:00-05:00,NUVA,negative
927045.0,"UBS Maintains Sell on NuVasive, Lowers Price Target to $42",2019-01-08 09:15:00-05:00,NUVA,negative
927046.0,65 Biggest Movers From Yesterday,2019-01-08 05:16:00-05:00,NUVA,neutral
927047.0,NuVasive shares are trading lower after the company missed Q4 sales estimates.,2019-01-07 11:01:00-05:00,NUVA,negative
927048.0,NuVasive Sees FY2018 Sales $1.10B vs $1.11B Est,2019-01-07 08:34:00-05:00,NUVA,neutral
927049.0,NuVasive Sees Q4 Sales $288.0M vs $294.35M Est,2019-01-07 08:33:00-05:00,NUVA,neutral
927050.0,"Morgan Stanley Maintains Equal-Weight on NuVasive, Lowers Price Target to $57",2019-01-02 09:42:00-05:00,NUVA,negative
927051.0,"Credit Suisse Initiates Coverage On NuVasive with Outperform Rating, Announces $66 Price Target",2018-12-18 07:44:00-05:00,NUVA,positive
927052.0,NuVasive Announces Receipt Of FDA 501(k) Clearance For Expanded Use Of Its Monolith Corpectomy System,2018-12-10 08:39:00-05:00,NUVA,neutral
927053.0,NuVasive Receives FDA 510(k) Clearance for Expanded Use of its Monolith Corpectomy System,2018-12-10 08:38:00-05:00,NUVA,neutral
927054.0,"UBS Initiates Coverage On NuVasive with Sell Rating, Announces $54 Price Target",2018-11-28 08:12:00-05:00,NUVA,neutral
927055.0,82 Biggest Movers From Yesterday,2018-11-01 04:38:00-04:00,NUVA,neutral
927056.0,66 Stocks Moving In Wednesday's Mid-Day Session,2018-10-31 12:50:00-04:00,NUVA,neutral
927057.0,"BMO Capital Maintains Market Perform on NuVasive, Lowers Price Target to $68",2018-10-31 10:46:00-04:00,NUVA,negative
927058.0,38 Stocks Moving In Wednesday's Pre-Market Session,2018-10-31 08:20:00-04:00,NUVA,neutral
927059.0,"UPDATE: NuVasive Raises FY18 Sales Guidance From $1.095B-$1.105B To $1.105B-$1.11B vs $1.1B Estimate, Cuts Adj. EPS From $2.37-$2.40 To $2.15-$2.23 vs $2.38 Est.",2018-10-30 16:34:00-04:00,NUVA,negative
927060.0,"NuVasive Raises FY18 Sales Guidance, Cuts Adj. EPS Guidance",2018-10-30 16:34:00-04:00,NUVA,negative
927061.0,"NuVasive Q3 EPS $0.56 Misses $0.62 Estimate, Sales $271.301M Beat $265.44M Estimate",2018-10-30 16:33:00-04:00,NUVA,negative
927062.0,NuVasive Reports J. Christopher Berry To Succeed Gregory Lucier As CEO,2018-10-19 08:31:00-04:00,NUVA,positive
927063.0,NuVasive Earlier Announced Strategic Partnership With Biedermann Technologies To Access Intellectual Property And Co-Develop Complex Spine Solutions,2018-10-09 08:25:00-04:00,NUVA,positive
927064.0,"NuVasive Wins 3-Year Sole Source Supplier contract For Intraoperative Neuromonitoring Services With Premier, No Terms Disclosed",2018-10-08 08:33:00-04:00,NUVA,positive
927065.0,"Stocks Which Set New 52-Week High Yesterday, October 2nd",2018-10-03 12:59:00-04:00,NUVA,neutral
927066.0,"Baird Upgrades NuVasive to Outperform, Raises Price Target to $82",2018-09-27 08:49:00-04:00,NUVA,neutral
927067.0,"NuVasive Enrolls First Patients In Long-Term, Controlled Study Evaluating Advanced Implants' Effects On Fusion And Clinical Outcomes In XLIF Procedures",2018-09-26 08:33:00-04:00,NUVA,positive
927068.0,10 Biggest Price Target Changes For Tuesday,2018-09-25 09:58:00-04:00,NUVA,neutral
927069.0,"Morgan Stanley Maintains Equal-Weight on NuVasive, Raises Price Target to $77",2018-09-25 07:37:00-04:00,NUVA,neutral
927070.0,"Stocks Which Set New 52-Week High Friday, September 14th",2018-09-17 09:28:00-04:00,NUVA,neutral
927071.0,"Canaccord Genuity Maintains Buy on NuVasive, Raises Price Target to $80",2018-09-17 07:41:00-04:00,NUVA,neutral
927072.0,"Stocks Which Set New 52-Week High Yesterday, September 13th",2018-09-14 09:26:00-04:00,NUVA,neutral
927073.0,"Stocks Which Set New 52-Week High Yesterday, September 12",2018-09-13 09:44:00-04:00,NUVA,neutral
927074.0,"The Daily Biotech Pulse: Progenics Posts Mixed Trial Results, Antitrust Nod For Galapagos-MorphoSys Collaboration, New CEO For Biopharmx",2018-09-13 08:42:00-04:00,NUVA,neutral
927075.0,"Stocks Which Set New 52-Week High Yesterday, September 11th",2018-09-12 12:17:00-04:00,NUVA,neutral
927076.0,"Stocks Which Set New 52-Week High Yesterday, August 23rd",2018-08-24 09:11:00-04:00,NUVA,neutral
927077.0,"Stocks Which Set New 52-Week High Yesterday, August 16th",2018-08-17 10:39:00-04:00,NUVA,neutral
927078.0,"NuVasive Reports Partnership With Siemens Related To Spine Surgery, No Terms Disclosed",2018-08-09 08:33:00-04:00,NUVA,negative
927079.0,"UPDATE: NuVasive Cuts FY18 Adj. EPS From $2.44-$2.47 To $2.37-$2.40 vs $2.44 Estimate, Reaffirms Sales Guidance $1.095B-$1.105B vs $1.1B Est.",2018-07-31 16:11:00-04:00,NUVA,negative
927080.0,NuVasive Cuts FY18 Guidance,2018-07-31 16:10:00-04:00,NUVA,negative
927081.0,"NuVasive Q2 EPS $0.58, Inline, Sales $281.564M Beat $276.26M Estimate",2018-07-31 16:09:00-04:00,NUVA,neutral
927082.0,"Earnings Scheduled For July 31, 2018",2018-07-31 04:37:00-04:00,NUVA,neutral
927083.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Earnings And IPOs",2018-07-28 14:04:00-04:00,NUVA,neutral
927084.0,Nuvasive Earlier Launched MAGEC X For Early Onset Scoliosis Treatment,2018-07-19 08:04:00-04:00,NUVA,positive
927085.0,NuVasive Earlier Introduced Low-Profile Modular Implants For Posterior Fixation,2018-07-16 08:21:00-04:00,NUVA,neutral
927086.0,"NuVasive Unveils XLIF Lordotic Expandable Interbody System, Which Received FDA 510(k) Clearance at IMAST 2018",2018-07-10 06:13:00-04:00,NUVA,neutral
927087.0,JP Morgan Downgrades NuVasive to Neutral,2018-06-21 07:50:00-04:00,NUVA,positive
927088.0,First Porous PEEK Spinal Implant Clinical Study Validates NuVasive Advanced Materials Science Technology In Treating Degenerative Cervical Disc Disease,2018-06-20 08:43:00-04:00,NUVA,positive
927089.0,NuVasive Launches AttraX Scaffold Biologic Bone Graft With Optimized Surface To Drive Increased Bone Formation And Reports First Clinical Use,2018-06-12 08:39:00-04:00,NUVA,positive
927090.0,Cantor Fitzgerald Taps Spinal Stocks: 4 Top Picks,2018-06-03 18:06:00-04:00,NUVA,positive
927091.0,"Benzinga's Top Upgrades, Downgrades For June 1, 2018",2018-06-01 09:26:00-04:00,NUVA,positive
927092.0,"Cantor Fitzgerald Initiates Coverage On NuVasive with Neutral Rating, Announces $54 Price Target",2018-06-01 08:00:00-04:00,NUVA,neutral
927093.0,"Benzinga's Top Upgrades, Downgrades For May 2, 2018",2018-05-02 09:15:00-04:00,NUVA,positive
927094.0,BMO Capital Downgrades NuVasive to Market Perform,2018-05-02 07:50:00-04:00,NUVA,neutral
927095.0,"NuVasive Reaffirms FY18 Adj. EPS Outlook $2.44-$2.47 vs $2.46 Est., Sales $1.095B-$1.105B vs $1.1B Est.",2018-05-01 17:09:00-04:00,NUVA,neutral
927096.0,NuVasive Reports Q1 2018  EPS of $0.39 vs $0.45 Est Revenue of $260.5M vs $259.49M Est,2018-05-01 16:02:00-04:00,NUVA,neutral
927097.0,"Goldman Sachs Initiates Coverage On NuVasive with Neutral Rating, Announces $47.00 Price Target",2018-04-04 08:36:00-04:00,NUVA,neutral
927098.0,"Morgan Stanley Maintains Equal-Weight on NuVasive, Lowers price target to $55.00",2018-02-27 10:25:00-05:00,NUVA,negative
927099.0,"Leerink Swann Maintains Market Perform on NuVasive, Raises Price Target to $52.00",2018-02-27 08:43:00-05:00,NUVA,neutral
927100.0,"NuVasive Sees FY18 Adj. EPS $2.44-$2.47 vs $2.37 Est., Sales $1.095B-$1.105B vs $1.09B Est.",2018-02-26 16:12:00-05:00,NUVA,neutral
927101.0,"NuVasive Reports Q4 Adj. EPS $0.56 vs $0.45 Est., Sales $271.7M vs $258.8M Est.",2018-02-26 16:10:00-05:00,NUVA,neutral
927102.0,"Earnings Scheduled For February 26, 2018",2018-02-26 04:22:00-05:00,NUVA,neutral
927103.0,13F From Rosenstein's JANA Shows Liquidated Stake In NuVasive,2018-02-14 16:43:00-05:00,NUVA,neutral
927104.0,"Benzinga's Top Upgrades, Downgrades For February 1, 2018",2018-02-01 09:15:00-05:00,NUVA,positive
927105.0,"The Market In 5 Minutes: Facebook Earnings, Jobless Claims Fall, Wynn Fallout",2018-02-01 09:04:00-05:00,NUVA,neutral
927106.0,Leerink Swann Downgrades NuVasive to Market Perform,2018-02-01 06:56:00-05:00,NUVA,neutral
927107.0,"Benzinga's Top Upgrades, Downgrades For January 17, 2018",2018-01-17 09:52:00-05:00,NUVA,positive
927108.0,Wells Fargo Downgrades NuVasive to Market Perform,2018-01-17 07:11:00-05:00,NUVA,positive
927109.0,Mid-Afternoon Market Update: NASDAQ Gains 0.2%; GoPro Shares Spike Higher,2018-01-08 14:31:00-05:00,NUVA,positive
927110.0,NuVasive Sees Q4 Sales ~$272M vs $272.9M Est.; Sees FY17 Sales ~$1.03B vs $1.03B Est.,2018-01-08 08:34:00-05:00,NUVA,neutral
927111.0,"NuVaisve To Acquire SafePassage, No Terms Disclosed",2017-12-12 16:02:00-05:00,NUVA,negative
927112.0,"13F Filing Shows Jana Partners Exited Home Depot and Hewlett Packard Enterprise Stakes, Reduced Gardner Denver and Nuvasive Stakes",2017-11-14 12:00:00-05:00,NUVA,neutral
927113.0,"NuVasive Lowers FY17 Adj. EPS Outlook From $2.00 to $1.91 vs $1.99 Est., Sales From $1.065B to $1.03B vs $1.06B Est.",2017-10-24 16:08:00-04:00,NUVA,negative
927114.0,"NuVasive Reports Q3 Adj. EPS $0.52 vs $0.48 Est., Sales $247.4M vs $255.36M Est.",2017-10-24 16:07:00-04:00,NUVA,neutral
927115.0,NuVasive Announces $100M Share Buyback,2017-10-24 16:04:00-04:00,NUVA,positive
927116.0,"NuVasive Highlights Launch Of 3D-Printed Porous Titanium Implant, Modulus XLIF",2017-10-18 16:14:00-04:00,NUVA,neutral
927117.0,NuVasive Receives Expanded 510(k) Clearance For TLX Interbody System Used In TLIF Procedures,2017-10-16 08:39:00-04:00,NUVA,neutral
927118.0,NuVasive Reports Expanded FDA 510(k) Clearance For PRECICE System,2017-10-12 08:31:00-04:00,NUVA,neutral
927119.0,Alphatec Issues Release Denouncing 'Baseless' NuVasive Complaint,2017-10-11 09:01:00-04:00,NUVA,negative
927120.0,Nuvasive Files Lawsuit Against Its Fmr. Chairman Patrick Miles Alleging Miles Engaged In Scheme To Divert Corporate Opportunities,2017-10-10 16:38:00-04:00,NUVA,positive
927121.0,NuVasive Holding Mainstay Annual General Meeting Today,2017-09-22 08:56:00-04:00,NUVA,neutral
927122.0,The Market In 5 Minutes,2017-09-20 07:50:00-04:00,NUVA,neutral
927123.0,GlassHouse: NuVasive Using The 'Valeant Playbook' To Deceive Investors,2017-09-19 11:01:00-04:00,NUVA,negative
927124.0,"UPDATE: GlassHouse Sets $24.18 Price Target On NuVasive Shares, Representing Possible Downside Of ~57% From Current Levels",2017-09-19 10:59:00-04:00,NUVA,positive
927125.0,"UPDATE: GlassHouse On NuVasive Highlights Recent Pres/COO, CFO Departures, Warns Co. Has 'Similar Accounting Concerns To Electronics For Imaging'",2017-09-19 10:59:00-04:00,NUVA,negative
927126.0,GlassHouse Research Issues Negative Research Report On NuVasive,2017-09-19 10:59:00-04:00,NUVA,negative
927127.0,"Wall Street's M&A Chatter From September 7: Amcor-Bemis, NuVasive-Vertera Spine, Newell-Chesapeake Bay Candle",2017-09-08 07:46:00-04:00,NUVA,neutral
927128.0,"NuVasive Announces Acquisition Of Vertera Spine, Terms Not Disclosed",2017-09-07 10:44:00-04:00,NUVA,neutral
927129.0,Nuvasive Receives 510(K) Clearnace For Leading EOS Innovation,2017-09-06 08:02:00-04:00,NUVA,positive
927130.0,"Benzinga's Top Upgrades, Downgrades For August 28, 2017",2017-08-28 09:24:00-04:00,NUVA,positive
927131.0,Needham Downgrades NuVasive to Underperform,2017-08-28 08:06:00-04:00,NUVA,neutral
927132.0,NuVasive Names Rajesh J. Asarpota CFO,2017-08-15 07:30:00-04:00,NUVA,neutral
927133.0,20 Biggest Mid-Day Losers For Friday,2017-07-28 13:09:00-04:00,NUVA,negative
927134.0,"Benzinga's Top Upgrades, Downgrades For July 28, 2017",2017-07-28 09:15:00-04:00,NUVA,positive
927135.0,Baird Downgrades NuVasive to Neutral,2017-07-28 08:26:00-04:00,NUVA,neutral
927136.0,22 Stocks Moving In Friday's Pre-Market Session,2017-07-28 08:07:00-04:00,NUVA,neutral
927137.0,"NuVasive Sees FY17 EPS $2.00 vs $2.01 Est., Sales $1.065B vs $1.07B Est.",2017-07-27 16:12:00-04:00,NUVA,neutral
927138.0,"NuVasive Announces Resignation of CFO Quentin Blackford, President And COO Jason Hannon",2017-07-27 16:10:00-04:00,NUVA,negative
927139.0,"NuVasive Reports Q2 Adj. EPS $0.46 vs $0.44 Est., Sales $260.6M vs $262M Est.",2017-07-27 16:03:00-04:00,NUVA,neutral
927142.0,"Buy The Dip In NuVasive Shares, Says Canaccord Genuity",2017-04-26 13:23:00-04:00,NUVA,positive
927143.0,"NuVasive Shares Down ~5% Following Mixed Q1 Results, Soft FY17 Outlook; Canaccord Earlier Said 'We Would Be Buyers on Any Weakness,' Raised Price Target from $82 to $84",2017-04-26 10:35:00-04:00,NUVA,positive
927144.0,"NuVasive Sees FY17 Sales ~$1.065B vs $1.07B Est., EPS ~$2.00 vs $2.02 Est.",2017-04-25 16:09:00-04:00,NUVA,neutral
927145.0,"NuVasive Reports Q1 EPS $0.38 vs $0.38 Est., Sales $250M vs $250.8M Est.",2017-04-25 16:08:00-04:00,NUVA,neutral
927146.0,NuVasive Reports Received FDA Clearance for Cervical Interbody Implant System,2017-03-29 09:04:00-04:00,NUVA,neutral
927147.0,"NuVasive Reports Q4 EPS $0.53 vs. Est. $0.51, Rev. $271.1M vs. Est. $261M",2017-02-09 16:11:00-05:00,NUVA,neutral
927148.0,"Nuvasive Sees FY16 Rev. ~$956M vs. Est. $952M, FY17 Rev. $1.065B vs. Est. $1.07B",2017-01-09 07:55:00-05:00,NUVA,neutral
927149.0,NuVasive Will Resume XLIF Procedures in Japan in Q1,2016-12-29 07:07:00-05:00,NUVA,neutral
927150.0,"10 Stocks That Rallied Four Days, Then Sold Off Yesterday",2016-12-01 05:36:00-05:00,NUVA,neutral
927151.0,Benzinga's Top Initiations,2016-11-30 09:25:00-05:00,NUVA,positive
927152.0,"Aegis Capital Initiates Coverage On NuVasive at Buy, Announces $72.00 Target",2016-11-30 07:14:00-05:00,NUVA,neutral
927153.0,Insiders Take Advantage Of NuVasive Pullback After Earnings,2016-11-03 15:36:00-04:00,NUVA,positive
927154.0,NuVasive Secures Magnetic Resonance (MR) FDA Conditional Clearance for MAGEC System,2016-10-27 07:49:00-04:00,NUVA,positive
927155.0,15 Stocks Which Plummeted Three Days On Increasing Volume,2016-10-27 07:25:00-04:00,NUVA,neutral
927156.0,"NuVasive Reaffirms FY16 Sales ~$952M vs $962.4M Est., Adj. EPS ~$1.64 vs $1.65 Est.",2016-10-25 17:01:00-04:00,NUVA,neutral
927157.0,"NuVasive Reports Q3 EPS $0.40 vs. Est. $0.40, Rev. $239.6M vs. Est. $243.5M",2016-10-25 17:00:00-04:00,NUVA,neutral
927158.0,NuVasive Postpones Q3 Earnings Announcement From Wednesday Oct. 26 To Tuesday Oct. 25th,2016-10-18 16:11:00-04:00,NUVA,negative
927159.0,20 Stocks Which Rallied Three Days On Increasing Volume,2016-09-23 09:19:00-04:00,NUVA,neutral
927160.0,15 Biggest Mid-Day Gainers For Wednesday,2016-09-21 12:49:00-04:00,NUVA,neutral
927161.0,Benzinga's Volume Movers,2016-09-21 10:48:00-04:00,NUVA,neutral
927162.0,20 Stocks Moving In Wednesday's Pre-Market Session,2016-09-21 08:31:00-04:00,NUVA,neutral
927163.0,S&P Dow Jones Indices Announces 'The Cooper Companies Set to Join the S&P 500; Northwestern and NuVasive to Join S&P MidCap 400; SPS Commerce and Fox Factory to Join S&P SmallCap 600',2016-09-20 17:18:00-04:00,NUVA,positive
927164.0,NuVasive Gets FDA 501(k) Clearance - Dow Jones,2016-09-19 07:27:00-04:00,NUVA,neutral
927165.0,The Market In 5 Minutes: The Fed And IEA Confuse The Market,2016-09-13 08:51:00-04:00,NUVA,negative
927166.0,"NuVasive Reaffirms FY16 Outlook: Adj. EPS $1.64 vs $1.65 Est., Sales $962M vs $962.4M Est.",2016-09-12 16:09:00-04:00,NUVA,neutral
927167.0,"NuVasive Names Jason Hannon Pres, COO; Patrick Miles Will Assume Role of Vice Chair",2016-09-12 16:09:00-04:00,NUVA,neutral
927168.0,Here Are All The CEOs Benzinga Spoke With In 2016,2016-08-16 11:30:00-04:00,NUVA,neutral
927169.0,"After-Market Gainers: AAPL Up 6.06%, SWKS 2.44%, QRVO 2.80%, PNRA 4.54%, LOGM 19.48%, EW 6.56%, JBT 2.53%, NUVA 2.10%",2016-07-26 17:11:00-04:00,NUVA,neutral
927170.0,NuVasive Reports Q2 Adj. EPS $0.40 vs $0.36 Est.,2016-07-26 16:07:00-04:00,NUVA,neutral
927172.0,7 Largest Price Target Changes For Wednesday,2016-07-13 09:42:00-04:00,NUVA,neutral
927173.0,Benzinga's Top Upgrades,2016-07-13 08:57:00-04:00,NUVA,positive
927174.0,"JPMorgan Sees Double-Digit Sales Ahead For NuVasive, Upgrades To Overweight",2016-07-13 08:08:00-04:00,NUVA,negative
927175.0,"JP Morgan Upgrades NuVasive to Overweight, Raises PT to $74.00",2016-07-13 06:12:00-04:00,NUVA,neutral
927176.0,"NuVasive Agrees to Settle Patent Litigation With Medtronic, NuVasive To Make One-Time Payment Of $45M  To Medtronic",2016-06-30 16:08:00-04:00,NUVA,neutral
927177.0,"Exclusive: NuVasive CEO Talks M&A, Brazil, And The Company's Biggest Weakness",2016-06-14 12:45:00-04:00,NUVA,negative
927178.0,NuVasive CEO At William Blair Conf. Says Company Sees Operating Margins At 15.8% Due To Some Headwinds From Recent Acquisition,2016-06-14 12:35:00-04:00,NUVA,neutral
927179.0,NuVasive to Buy Biotronic NeuroNetwork for $98M in Cash,2016-06-06 16:06:00-04:00,NUVA,neutral
927180.0,"Barclays Bullish On NuVasive, Globus Medical, Dislikes LDR Holding",2016-05-27 09:36:00-04:00,NUVA,negative
927181.0,Benzinga's Top Upgrades,2016-05-27 09:19:00-04:00,NUVA,positive
927182.0,The Market In 5 Minutes: Happy Memorial Day Weekend,2016-05-27 08:52:00-04:00,NUVA,positive
927183.0,"Barclays Upgrades NuVasive to Overweight, Raises PT to $63.00",2016-05-27 03:52:00-04:00,NUVA,negative
927184.0,"Cowen & Company Maintains Outperform on NuVasive, Raises PT to $63.00",2016-04-27 07:37:00-04:00,NUVA,neutral
927185.0,"NuVasive Sees FY16 Rev. ~$928M vs. Est. $924M, EPS ~$1.48 vs. Est. $1.49",2016-04-26 16:40:00-04:00,NUVA,neutral
927186.0,"NuVasive Reports Q1 EPS $0.31 vs. Est. $0.27, Rev. $215.1M vs. Est. $205.67M",2016-04-26 16:39:00-04:00,NUVA,neutral
927187.0,NuVasive Reports Regulatory Approval of reline Posterior Fixation Technology in Japan,2016-03-09 07:06:00-05:00,NUVA,positive
927188.0,"The Market In 5 Minutes: Tuesday, March 8, 2016",2016-03-08 12:26:00-05:00,NUVA,neutral
927189.0,"NuVasive Reports Deal to Buy Mega Surgical, No Terms Disclosed",2016-03-07 16:33:00-05:00,NUVA,negative
927190.0,"NuVasive Sees FY16 Sales ~$923M vs $881M Est., Adj. EPS ~$1.48 vs $1.49 Est.",2016-02-11 16:08:00-05:00,NUVA,neutral
927191.0,"NuVasive Reports Q4 Adj. EPS $0.35 vs $0.31 Est., Sales $215.3M vs $215.3M Est.",2016-02-11 16:07:00-05:00,NUVA,neutral
927192.0,NuVasive Sees Q4 Sales $215.0M vs $214.98M Est,2016-01-12 07:03:00-05:00,NUVA,neutral
927193.0,NuVasive Sees FY2016 Sales $870.0M vs $880.98M Est,2016-01-12 07:03:00-05:00,NUVA,neutral
927194.0,NuVasive Sees FY2015 Sales $811.0M vs $813.71M Est,2016-01-12 07:02:00-05:00,NUVA,neutral
927195.0,"NuVasive Announces Acquisition Of Ellipse Technologies, Notes 'Potential To Become The Standard Of Care'",2016-01-06 09:35:00-05:00,NUVA,positive
927196.0,NuVasive To Acquire Ellipse Technologies For $380M Cash And $30M Milestone Potential,2016-01-05 16:16:00-05:00,NUVA,neutral
927197.0,Benzinga's Top Upgrades,2015-12-11 08:50:00-05:00,NUVA,positive
927198.0,Bank of America Upgrades NuVasive to Neutral,2015-12-11 07:53:00-05:00,NUVA,neutral
927199.0,"Nuvasive In 8-K, Reiterates FY15 Rev. Guidance Of $810M vs. Est. $811.01M, Sees FY16 Rev. $870M vs. Est. $871.24M",2015-12-10 07:09:00-05:00,NUVA,neutral
927200.0,"Nuvasive Earlier Saw FY15 Rev. ~$810M vs. Est. $813.34M, EPS ~$1.25 vs. Est. $1.19",2015-10-27 16:38:00-04:00,NUVA,neutral
927201.0,"NuVasive Reports Q3 EPS $0.35 vs. Est. $0.27, Rev. $200.5M vs. Est. $200.2M",2015-10-27 16:37:00-04:00,NUVA,neutral
927202.0,NuVasive Receives First Ever FDA 510(k) Clearance of Cervical Corpectomy Cage,2015-10-12 07:00:00-04:00,NUVA,neutral
927203.0,Benzinga's Top Upgrades,2015-10-06 09:16:00-04:00,NUVA,positive
927204.0,NuVasive Upgraded To Buy At Canaccord On Leverage,2015-10-06 08:08:00-04:00,NUVA,neutral
927205.0,"Northland Securities Upgrades NuVasive to Outperform, Raises PT to $68.00",2015-07-29 09:23:00-04:00,NUVA,positive
927206.0,"Brean Capital Maintains Buy on NuVasive, Raises PT to $56.00",2015-07-29 06:24:00-04:00,NUVA,neutral
927207.0,"UPDATE: NuVasive Raises FY15 Adj. EPS from $1.10 to ~$1.17 vs $1.12 Est., Sales ~$810M vs $812M Est.",2015-07-28 16:11:00-04:00,NUVA,neutral
927208.0,"NuVasive Reports Q2 Adj. EPS $0.31 vs $0.25 Est., Sales $202.9M vs $200.7M Est.; Raises FY15 Outlook",2015-07-28 16:10:00-04:00,NUVA,neutral
927209.0,NuVasive Reports Settlement With U.S.,2015-07-28 16:07:00-04:00,NUVA,neutral
927210.0,"NuVasive Names  Pat Miles COO, Quentin Blackford CFO",2015-07-13 16:06:00-04:00,NUVA,neutral
927211.0,"Nuvasive Chairman Lucier Buys 10,000 Shares @$49.10/Share -Form 4",2015-06-11 16:25:00-04:00,NUVA,positive
927212.0,Piper Jaffray Met With NuVasive Management And Came Away 'Still Confident',2015-06-11 08:48:00-04:00,NUVA,positive
927213.0,"Goldman Sachs' New Pair Trade? Bull Zeltiq Aesthetics, Bear NuVasive",2015-06-03 15:27:00-04:00,NUVA,neutral
927214.0,Morning Market Losers,2015-06-03 09:52:00-04:00,NUVA,negative
927215.0,Benzinga's Top Downgrades,2015-06-03 09:42:00-04:00,NUVA,positive
927216.0,Goldman Sachs Downgrades NuVasive To  Neutral,2015-06-03 09:04:00-04:00,NUVA,neutral
927217.0,Benzinga's Top #PreMarket Losers,2015-06-03 08:17:00-04:00,NUVA,negative
927218.0,Goldman Sachs Downgrades NuVasive to Neutral,2015-06-03 05:21:00-04:00,NUVA,neutral
927219.0,NuVasive Names Gregory Lucier CEO,2015-05-26 08:30:00-04:00,NUVA,neutral
927220.0,"NuVasive Reports Q1 EPS $0.61 Vs Est $0.22, May Not COmpare, Sales $192.4M Vs Est $189.30M",2015-05-04 16:10:00-04:00,NUVA,neutral
927221.0,"Earnings Scheduled For May 4, 2015",2015-05-04 04:06:00-04:00,NUVA,neutral
927222.0,"NuVasive Reports Deal in Principle to Settle OIG Matter, Will Pay $13.8M to US",2015-04-29 08:05:00-04:00,NUVA,negative
927223.0,Canaccord Just Downgraded NuVasive And Shares Are Falling,2015-04-15 09:33:00-04:00,NUVA,positive
927224.0,Benzinga's Top Downgrades,2015-04-15 09:15:00-04:00,NUVA,positive
927225.0,Canaccord Genuity Downgrades NuVasive To Hold,2015-04-15 07:40:00-04:00,NUVA,neutral
927226.0,"Canaccord Genuity Downgrades NuVasive to Hold, Lowers PT to $49.00",2015-04-15 06:30:00-04:00,NUVA,negative
927227.0,Jefferies: 10 Buyout Targets To Own During The M&A Boom,2015-04-13 16:17:00-04:00,NUVA,neutral
927228.0,Bank of America Downgrades NuVasive to Underperform,2015-04-02 07:23:00-04:00,NUVA,neutral
927229.0,Shares of NuVasive to Resume Trade at 9 a.m. EDT,2015-04-01 08:36:00-04:00,NUVA,positive
927230.0,NuVasive Expecting Q1 Sales $190M+ vs $189.3M Est.,2015-04-01 08:31:00-04:00,NUVA,neutral
927231.0,"NuVasive Announces Leadership Transition: Chair, CEO Alex Lukianov to Step Down, Gregory Lucier Named as Replacement",2015-04-01 08:30:00-04:00,NUVA,neutral
927232.0,Shares of NuVasive Halted News Pending,2015-04-01 08:25:00-04:00,NUVA,positive
927233.0,NuVasive Announces Successful Appeal of Medtronic Verdict,2015-03-03 08:00:00-05:00,NUVA,positive
927234.0,"NuVasive Reports COO Keith Valentine to Resign; Pat Miles Named as Pres, COO",2015-01-12 16:09:00-05:00,NUVA,negative
927235.0,NuVasive Sees FY2015 Sales $810.0M vs $811.70M Est,2015-01-12 16:01:00-05:00,NUVA,neutral
927236.0,NuVasive Reports Prelim. FY2014 Sales $761.0M vs $758.0M Est,2015-01-12 16:01:00-05:00,NUVA,neutral
927237.0,"RBC Capital Upgrades NuVasive to Outperform, Raises PT to $56.00",2015-01-08 06:27:00-05:00,NUVA,neutral
927238.0,"Brean Capital Reiterates Buy on NuVasive, Inc., Raises PT to $53.00",2014-12-04 05:12:00-05:00,NUVA,neutral
927239.0,"Wells Fargo Upgrades NuVasive, Inc. to Outperform",2014-11-17 09:26:00-05:00,NUVA,positive
927240.0,NuVasive Focused On Surgeon Support And Showcasing Industry-Leading Products At North American Spine Society 29th Annual Meeting,2014-11-10 16:25:00-05:00,NUVA,positive
927241.0,"NuVasive, Inc. Sees FY2014 EPS $1.12 vs $1.12 Est; Sees Sales $755.0M-755.00 vs $748.0M Est",2014-10-30 16:57:00-04:00,NUVA,neutral
927242.0,"NuVasive, Inc. Reports Q3 EPS of $0.19 vs $0.25 Est",2014-10-30 16:07:00-04:00,NUVA,neutral
927243.0,"NuVasive Reports Q2 Adj. EPS $0.28 vs $0.25; Raises FY EPS Guidance from ~$1.06 to ~$1.11, Sales from ~$725M to ~$745M",2014-07-29 16:34:00-04:00,NUVA,neutral
927244.0,"NuVasive Reports Q2 EPS loss $0.09, Revenues $190.7M",2014-07-29 16:32:00-04:00,NUVA,negative
927245.0,Benzinga's Top Downgrades,2014-05-21 07:58:00-04:00,NUVA,positive
927246.0,"Needham Downgrades NuVasive, Inc. to Hold, Removes $40.00 PT",2014-05-21 06:43:00-04:00,NUVA,neutral
927247.0,NuVassive Announces Favorable Settlement with Cadwell,2014-05-06 08:32:00-04:00,NUVA,positive
927248.0,"NuVasive Announces CFO Lambert Intends to Retire, Blackford to Succeed",2014-04-29 16:41:00-04:00,NUVA,positive
927249.0,"NuVasive, Inc. Reports Q1 EPS of $0.29 vs $0.23 Est; Revenue of $177.50M vs $171.34M Est",2014-04-29 16:31:00-04:00,NUVA,neutral
927250.0, NuVasive Announces $30M Unfavorable Jury Verdict for Use of Trade-Name 'NeuroVision' 8-K,2014-04-04 06:21:00-04:00,NUVA,positive
927251.0,"NuVasive, Inc. Reports Q4 EPS of $0.37 vs $0.32 Est; Revenue of $190.80M vs $181.24M Est",2014-03-03 16:30:00-05:00,NUVA,neutral
927252.0,"Earnings Scheduled For March 3, 2014",2014-03-03 04:42:00-05:00,NUVA,neutral
927253.0,"Leerink Swann Upgrades NuVasive, Inc. to Outperform, Raises PT to $45.00",2014-01-22 08:11:00-05:00,NUVA,neutral
927254.0,Stocks Hitting 52-Week Highs,2014-01-16 10:32:00-05:00,NUVA,neutral
927255.0,"Goldman Sachs Upgrades NuVasive, Inc. to Neutral",2014-01-16 07:23:00-05:00,NUVA,neutral
927256.0,Market Wrap For January 15: Bulls Take Over As Economic Growth Remains Healthy,2014-01-15 16:45:00-05:00,NUVA,positive
927257.0,Mid-Afternoon Market Update: Markets Nearly Erase Early Year Losses as The ExOne Continues to Drop,2014-01-15 15:59:00-05:00,NUVA,negative
927258.0,Mid-Day Market Update: Dow Jumps 120 Points; Fastenal Shares Drop On Downbeat Earnings,2014-01-15 13:44:00-05:00,NUVA,neutral
927259.0,Mid-Morning Market Update: Markets Rise; Bank of America Profit Beats Estimates,2014-01-15 11:31:00-05:00,NUVA,positive
927260.0,Benzinga's Volume Movers,2014-01-15 10:33:00-05:00,NUVA,neutral
927261.0,"NuVasive Reports Q4 Prelim. Sales $189M, FY13 Sales $683M, FY14 Sales ~$725M",2014-01-15 08:03:00-05:00,NUVA,neutral
927262.0,NuVasive Announces US Launch of ALIF ACR(TM),2013-12-17 08:35:00-05:00,NUVA,neutral
927263.0,NuVasive Names Gregory Lucier to Board,2013-12-04 09:00:00-05:00,NUVA,neutral
927264.0,Stocks Hitting 52-Week Highs,2013-10-30 10:23:00-04:00,NUVA,neutral
927265.0,"NuVasive, Inc. Raises FY2013 EPS Guidance from $1.00 to $1.14 vs $1.00 Est; Raises FY2013 Sales Guidance from $655.0M to $670.0M vs $657.90M Est",2013-10-29 16:35:00-04:00,NUVA,neutral
927266.0,"NuVasive, Inc. Reports Q3 EPS of $0.16 vs $0.24 Est; Revenue of $169.20M vs $158.48M Est",2013-10-29 16:31:00-04:00,NUVA,neutral
927267.0,"UPDATE: Goldman Sachs Downgrades NuVasive as Industry Headwinds, Valuation Pose Downside Risk",2013-10-14 11:29:00-04:00,NUVA,negative
927268.0,"BMO Capital Upgrades NuVasive, Inc. to Market Perform, Raises PT to $25.00",2013-10-14 08:10:00-04:00,NUVA,neutral
927269.0,Benzinga's Top Downgrades,2013-10-14 07:46:00-04:00,NUVA,positive
927270.0,"Goldman Sachs Downgrades NuVasive, Inc. to Sell, Lowers PT to $22.00",2013-10-14 07:16:00-04:00,NUVA,negative
927271.0,Benzinga's Top Initiations,2013-08-08 09:18:00-04:00,NUVA,positive
927272.0,"Needham Initiates Coverage on NuVasive, Inc. at Buy, Announces $28.00 PT",2013-08-08 07:59:00-04:00,NUVA,neutral
927273.0,"Market Wrap For Wednesday, July 31: Stocks Mostly Unchanged Despite Upbeat Data",2013-07-31 16:23:00-04:00,NUVA,neutral
927274.0,Mid-Afternoon Market Update: Fed Leaves Rates Unchanged; Green Dot Rises,2013-07-31 15:45:00-04:00,NUVA,neutral
927275.0,"First Analysis Downgraded NuVasive, Inc. to Equalweight, Maintains $25 PT",2013-07-31 10:37:00-04:00,NUVA,neutral
927276.0,Nuvasive Receives Subpoena from Office of Inspector General of US Department of Health and Human Services -10Q,2013-07-31 06:53:00-04:00,NUVA,positive
927277.0,"NuVasive, Inc. Reports Q2 EPS of $0.20 vs $0.24 Est; Revenue of $165.70M",2013-07-30 16:30:00-04:00,NUVA,neutral
927278.0,"Janney Capital Downgrades NuVasive to Neutral, Raises PT to $28.00",2013-07-25 08:49:00-04:00,NUVA,neutral
927279.0,UPDATE: BMO Capital Markets Downgrades NuVasive on Multiple Positive Factors,2013-07-15 11:16:00-04:00,NUVA,positive
927280.0,UPDATE: Canaccord Genuity Raises PT on NuVasive on Multiple Positive Factors,2013-06-19 11:11:00-04:00,NUVA,positive
927281.0,UPDATE: Barrington Raises PT on NuVaisve on Multiple Positive Factors,2013-05-21 08:42:00-04:00,NUVA,positive
927282.0,"Wallachbeth Capital Initiates Coverage on NuVasive, Inc. at Buy, Announces $27.00 PT",2013-05-17 08:14:00-04:00,NUVA,neutral
927283.0,"NuVasive Buys ANC, LLC, Spine Implant Manufacturer for $4.5M",2013-05-06 08:04:00-04:00,NUVA,neutral
927284.0,"Starbucks, Huntington Bancshares and Other Stocks Insiders Are Buying",2013-05-04 10:25:00-04:00,NUVA,neutral
927285.0,"NuVasive, Inc. Reports Q1 EPS of $0.02 vs $0.22 Est; Revenue of $159.50M vs $157.44M Est",2013-04-30 16:31:00-04:00,NUVA,neutral
927286.0,Nuvasive Received FDA Warning Letter Related to San Diego Plant,2013-03-18 09:03:00-04:00,NUVA,negative
927287.0,UPDATE: J.P. Morgan Raises PT on NuVasive Despite Limited Growth Expectations,2013-02-27 13:51:00-05:00,NUVA,negative
927288.0,"UPDATE: Goldman Sachs Reiterates Neutral Rating, Raises PT on NuVasive on 4Q2012 Revenue",2013-02-27 13:44:00-05:00,NUVA,neutral
927289.0,UPDATE: Piper Jaffray Raises PT to $24 on NuVasive; Q4 Sets Stage for Outperformance,2013-02-27 11:34:00-05:00,NUVA,neutral
927290.0,"UPDATE: Canaccord Genuity Reiterates Buy Rating, Raises PT on NuVasive Following Q4/12 Results",2013-02-27 11:01:00-05:00,NUVA,neutral
927291.0,"Mizuho Securities Downgraded NuVasive, Inc. to Neutral, Maintains $20.00 PT",2013-02-27 09:52:00-05:00,NUVA,positive
927292.0,UPDATE: BMO Capital Markets Raises PT on NuVasive on In-Line 4Q12,2013-02-27 09:41:00-05:00,NUVA,neutral
927293.0,"Goldman Sachs Maintains Neutral on NuVasive, Inc., Raises PT to $20.00",2013-02-27 08:26:00-05:00,NUVA,neutral
927294.0,"Piper Jaffray Maintains Overweight on NuVasive, Inc., Raises PT to $24.00",2013-02-27 08:20:00-05:00,NUVA,negative
927295.0,"JP Morgan Maintains Neutral on NuVasive, Inc., Raises PT to $21.00",2013-02-27 08:05:00-05:00,NUVA,positive
927296.0,"Canaccord Genuity Maintains Buy on NuVasive, Inc., Raises PT to $25.00",2013-02-27 08:03:00-05:00,NUVA,neutral
927297.0,"BMO Capital Maintains Market Perform on NuVasive, Inc., Raises PT to $18.00",2013-02-27 07:44:00-05:00,NUVA,neutral
927298.0,"NuVasive, Inc. Reports Q4 EPS of $0.34 vs $0.21 Est; Revenue of $165.80M vs $157.30M Est",2013-02-26 16:33:00-05:00,NUVA,neutral
927299.0,NuVasive Announces First Patient in Japan Treated with XLIF(R) Technique,2013-02-26 16:17:00-05:00,NUVA,neutral
927300.0,UPDATE: JP Morgan Raises PT to $20 on NuVasive; 2013 Outlook Likely Conservative,2013-02-26 13:16:00-05:00,NUVA,positive
927301.0,"JP Morgan Maintains Neutral on NuVasive, Inc., Raises PT to $20.00",2013-02-26 08:16:00-05:00,NUVA,positive
927302.0,"Earnings Scheduled For February 26, 2013",2013-02-26 04:24:00-05:00,NUVA,neutral
927303.0,Mid-Afternoon Market Update: NuVasive Rises While EXCO Resourced Drops,2013-01-09 15:52:00-05:00,NUVA,neutral
927304.0,"Mid-Day Market Update: Markets Remain Up, Dynavax Continues Rally",2013-01-09 14:19:00-05:00,NUVA,neutral
927305.0,"Nuvasive Reports Prelim. FY12 Sales ~$619M vs $604.4M, Had Seen $601-606M; Sees FY13 Sales ~$655M vs $638M ESt",2013-01-09 08:32:00-05:00,NUVA,neutral
927306.0,Benzinga's Top Upgrades,2013-01-09 07:11:00-05:00,NUVA,positive
927307.0,"UPDATE: BMO Capital Markets Upgrades Nuvasive to Market Perform, Raises PT",2013-01-04 12:29:00-05:00,NUVA,neutral
927308.0,"BMO Capital Upgrades NuVasive, Inc. to Market Perform, Raises PT to $17.00",2013-01-04 09:27:00-05:00,NUVA,neutral
927309.0,NuVasive Announces First Patient in the United States Treated With the PCM Cervical Disc Following FDA Approval  ,2012-12-20 14:40:00-05:00,NUVA,positive
927310.0,NuVasive Wins Regulatory Shonin Approval to Broaden Offering in Japan,2012-12-17 08:33:00-05:00,NUVA,positive
927311.0,NuVasive(R) Announces Release of $62.5M From Escrow Following Appeals Court Victory ,2012-12-13 16:50:00-05:00,NUVA,neutral
927312.0,NuVasive to Release $62.5M from Escrow Following Appeals Court Win,2012-12-13 16:49:00-05:00,NUVA,positive
927313.0,First Analysis Upgraded NuVasive from Equal-weight to Overweight,2012-11-16 10:16:00-05:00,NUVA,negative
927314.0,Nuvasive Resumes Trading,2012-10-26 12:30:00-04:00,NUVA,neutral
927315.0,PREVIEW: NuVasive to Resume Trading at 12:30pm,2012-10-26 12:05:00-04:00,NUVA,neutral
927316.0,NuVasive Announces PMA Approval of the PCM(R) Cervical Disc System,2012-10-26 12:02:00-04:00,NUVA,positive
927317.0,Nuvasive Halted Pending News,2012-10-26 12:00:00-04:00,NUVA,neutral
927318.0,Leerink Swann Downgraded NuVasive from Outperform to Market Perform,2012-10-25 10:52:00-04:00,NUVA,neutral
927319.0,Benzinga's Top Downgrades,2012-10-25 07:27:00-04:00,NUVA,positive
927320.0,UPDATE: Goldman Sachs Reduces PT to $16 on NuVasive on Sales Outlook,2012-10-24 14:22:00-04:00,NUVA,neutral
927321.0,"Goldman Sachs Maintains NuVasive at Neutral, Lowers PT from $17 to $16",2012-10-24 13:58:00-04:00,NUVA,negative
927322.0,From Earlier: Nuvasive's President of Global Sales Resigned,2012-10-08 07:53:00-04:00,NUVA,negative
927323.0,"JP Morgan  Maintains NuVasive at Neutral, Lowers PT from $28 to $21",2012-10-05 10:41:00-04:00,NUVA,positive
927324.0,Benzinga Mid-Afternoon Market Update ,2012-10-04 15:52:00-04:00,NUVA,neutral
927325.0,UPDATE: BMO Capital Markets Downgrades NuVasive to Underperform on Outlook  ,2012-10-04 12:45:00-04:00,NUVA,neutral
927326.0,Benzinga Mid-Day Market Update ,2012-10-04 12:27:00-04:00,NUVA,neutral
927327.0,Benzinga Mid-Morning Market Update,2012-10-04 10:22:00-04:00,NUVA,neutral
927328.0,Morning Market Losers,2012-10-04 09:59:00-04:00,NUVA,negative
927329.0,RBC Capital Markets Downgraded NuVasive from Outperform to Underperform,2012-10-04 09:43:00-04:00,NUVA,neutral
927330.0,Wells Fargo Downgraded NuVasive from Outperform to Market Perform,2012-10-04 09:43:00-04:00,NUVA,positive
927331.0,Brean Murray Carret Downgraded NuVasive from Buy to Hold,2012-10-04 09:43:00-04:00,NUVA,neutral
927332.0,"BMO Capital Markets Downgrades NuVasive from Market Perform to Underperform, Lowers PT from $23 to $15",2012-10-04 09:04:00-04:00,NUVA,negative
927333.0,Benzinga's Top Pre-Market Losers,2012-10-04 08:18:00-04:00,NUVA,negative
927334.0,Nuvasive Falls 30% Pre-Market on Lowered Guidance,2012-10-04 07:54:00-04:00,NUVA,negative
927335.0,Benzinga's Top Downgrades,2012-10-04 07:30:00-04:00,NUVA,positive
927336.0,"Goldman Sachs Maintains NuVasive at Neutral, Lowers PT from $23 to $19",2012-10-04 06:59:00-04:00,NUVA,negative
927337.0,"Canaccord Maintains NuVasive at Buy, Lowers PT from $27 to $21",2012-10-04 06:46:00-04:00,NUVA,negative
927338.0,"US Stock Futures Up; Jobless Claims, ECB Meeting In Focus",2012-10-04 06:09:00-04:00,NUVA,neutral
927339.0,"Stocks To Watch For October 4, 2012 ",2012-10-04 02:06:00-04:00,NUVA,neutral
927340.0,Nuvasive Falls 21% After-Hours on Lowered Guidance,2012-10-03 16:18:00-04:00,NUVA,negative
927341.0,"UPDATE: NuVasive Guides Q3 Prelim Revenue $147M, Had Seen $154.4M vs $153.4M Est",2012-10-03 16:07:00-04:00,NUVA,neutral
927342.0,"NuVasive Cuts Q3 Prelim Revenue, Forecast $147M",2012-10-03 16:06:00-04:00,NUVA,negative
927343.0,"Esterline, Janus Capital and Other Stocks Insiders Are Buying",2012-10-01 06:58:00-04:00,NUVA,neutral
927344.0,"Barclays Maintains NuVasive at Overweight, Raises PT from $25 to $27",2012-07-26 15:02:00-04:00,NUVA,negative
927345.0,UPDATE: Jefferies Increases PT on NuVasive from $20 to $27,2012-07-26 09:29:00-04:00,NUVA,neutral
927346.0,"Jefferies & Company Maintains NuVasive at Buy, Raises PT from $20 to $27",2012-07-26 07:45:00-04:00,NUVA,neutral
927347.0,"NuVasive Guides FY Revenue $625M, Had Seen $615M vs $623.2M Est",2012-07-25 16:36:00-04:00,NUVA,neutral
927348.0,NuVasive Reports Q2 EPS $0.27 vs $0.23 Est; Revenues $154.4M vs $154.18M Est,2012-07-25 16:32:00-04:00,NUVA,neutral
927349.0,"Goldman Sachs Maintains NuVasive at Neutral, Raises PT from $20 to $26",2012-07-02 08:35:00-04:00,NUVA,neutral
927350.0,"Medtronic, Snyder's-Lance and Other Stocks Insiders Are Buying",2012-06-26 10:13:00-04:00,NUVA,neutral
927351.0,"Bank of America Maintains NuVasive at Buy, Raises PO from $23 to $26",2012-06-21 06:40:00-04:00,NUVA,negative
927352.0,NuVasive Trading 25.2% Higher on Heavy Volume; Currently at $20.75,2012-05-01 15:39:00-04:00,NUVA,neutral
927353.0,NuVasive Up 20% After Q1 Earnings ,2012-05-01 13:46:00-04:00,NUVA,neutral
927354.0,Benzinga's Top Upgrades,2012-05-01 07:41:00-04:00,NUVA,positive
927355.0,UPDATE: NuVasive Reports Q1 EPS $0.2 vs $0.18 Est; Revenues $151.7M vs $143.64M Est,2012-04-30 16:42:00-04:00,NUVA,neutral
927356.0,NuVasive Reports Q1 EPS $0.20 vs $0.18 Est; Revs $151.7M vs $143.6M Est,2012-04-30 16:33:00-04:00,NUVA,neutral
927357.0,UPDATE: Goldman Sachs Raises PT to $16 on NuVasive,2012-03-09 10:02:00-05:00,NUVA,neutral
927358.0,Hearing Rodman & Renshaw Making Negative Comments on Nuvasive,2012-02-23 14:18:00-05:00,NUVA,negative
927359.0,NuVasive Reports Q4 EPS $0.27 vs $0.22 Est; Revenues $150.20M vs $148.39M Est	 				,2012-02-22 16:36:00-05:00,NUVA,neutral
927360.0,Top 4 Small-Cap Stocks In The Healthcare Sector With The Highest Cash,2012-02-22 04:24:00-05:00,NUVA,positive
927361.0,Benzinga's Top Downgrades,2012-02-13 07:26:00-05:00,NUVA,positive
927362.0,Top Trade Ideas for Friday Jan 27th,2012-01-26 17:41:00-05:00,NUVA,positive
927363.0,Top Trade Ideas for Friday Jan 27th,2012-01-26 17:41:00-05:00,NUVA,positive
927364.0,Medtronic Judge Denies Nuvasive Claim Patent is Invalid,2012-01-26 13:11:00-05:00,NUVA,negative
927365.0,UPDATE: BMO Capital Markets Increases Target to $16 on Nuvasive,2012-01-26 10:29:00-05:00,NUVA,neutral
927366.0,"NuVasive Halted, News Pending",2012-01-25 15:05:00-05:00,NUVA,neutral
927367.0,Medtronic Tentatively Loses Injunction Ruling Against Nuvasive -Bloomberg,2012-01-25 14:59:00-05:00,NUVA,negative
927368.0,Nuvasive Spiking Higher on Heavy Volume,2012-01-25 14:59:00-05:00,NUVA,neutral
927369.0,"UPDATE: Canaccord Genuity Upgrades NuVasive to Buy, Maintains $19 PT ",2012-01-23 10:47:00-05:00,NUVA,neutral
927370.0,Canaccord Upgrades NuVasive to Buy,2012-01-23 08:19:00-05:00,NUVA,neutral
927371.0,Notable Call Options Activity in NuVasive,2012-01-12 10:21:00-05:00,NUVA,neutral
927372.0,NuVasive Sees FY 2011 Revenue of $540M vs $538.46M Est ,2012-01-11 08:31:00-05:00,NUVA,neutral
927373.0,BMO Capital Markets Downgrades NuVasive to Market Perform,2012-01-05 09:01:00-05:00,NUVA,neutral
927374.0,NuVasive Hits 52-Week Low of $12.39,2011-11-25 11:47:00-05:00,NUVA,negative
927375.0,NuVasive Hits 52-Week Low of $12.82,2011-11-23 09:31:00-05:00,NUVA,negative
927376.0,NuVasive Hits 52-Week Low of $13.25,2011-11-22 09:33:00-05:00,NUVA,negative
927377.0,NuVasive Hits 52-Week Low of $13.54,2011-11-21 09:50:00-05:00,NUVA,negative
927378.0,Piper Jaffray Reiterates Overweight Rating On NuVasive after Analyst Meeting,2011-11-03 14:05:00-04:00,NUVA,negative
927379.0,UPDATE: Rodman & Renshaw Downgrades NuVasive to Market Perform,2011-11-01 09:31:00-04:00,NUVA,neutral
927380.0,"Rodman & Renshaw Downgrades NuVasive to Market Perform, $33 PT",2011-11-01 07:37:00-04:00,NUVA,neutral
927381.0,"Nuvasive Hits New 52-Week Low, $14.60",2011-10-31 09:34:00-04:00,NUVA,negative
927382.0,BofA/Merrill Lynch Reiterates Buy Rating on Nuvasive  ,2011-10-28 15:33:00-04:00,NUVA,neutral
927383.0,"Nuvasive Hits New 52-Week Low, $14.93",2011-10-28 14:38:00-04:00,NUVA,negative
927384.0,"Bank of America Lowers PO on Nuvasive from $40 to $23, Maintains Buy",2011-10-28 10:50:00-04:00,NUVA,negative
927385.0,"Nuvasive Sees 2011 EPS $1.01-$1.02 vs $1.06 Est, Had Seen $1.09-$1.12; Revenues $538M-$540 vs $538.8M Est, Had Seen $530M-$540M",2011-10-27 16:41:00-04:00,NUVA,neutral
927386.0,NuVasive Reports Q3 EPS $0.26 vs $0.23 Est; Revenues $132.9M vs $134.16M Est			,2011-10-27 16:40:00-04:00,NUVA,neutral
927387.0,"Zimmer Holdings Earnings Preview: Analysts Expect Higher EPS, Revenue",2011-10-25 17:01:00-04:00,NUVA,neutral
927388.0,Piper Jaffray Overweight on NuVasive  ,2011-10-10 07:45:00-04:00,NUVA,negative
927389.0,Piper Jaffray Overweight on NuVasive,2011-10-05 07:38:00-04:00,NUVA,negative
927390.0,"Barrington Research Reiterates NuVasive Outperform, PT",2011-09-30 16:23:00-04:00,NUVA,neutral
927391.0,J.P. Morgan Neutral on NuVasive,2011-09-30 07:39:00-04:00,NUVA,neutral
927392.0,Afternoon Losers; Casino Stocks Getting Hit After Typhoon in China ,2011-09-29 15:51:00-04:00,NUVA,negative
927393.0,NuVasive Signs Agreement to Acquire Impulse Monitoring  ,2011-09-29 06:49:00-04:00,NUVA,positive
927394.0,UPDATE: Jefferies Lowers Price Target on NuVasive to $30,2011-09-26 07:09:00-04:00,NUVA,negative
927395.0,Jefferies Lowers PT on NuVasive to $30,2011-09-26 06:25:00-04:00,NUVA,negative
927396.0,Piper Jaffray Reiterates Overweight on NuVasive,2011-09-23 09:58:00-04:00,NUVA,negative
927397.0,UPDATE: J.P. Morgan Lowers Price Target on NuVasive to $24,2011-09-22 08:57:00-04:00,NUVA,negative
927398.0,JP Morgan Lowers PT on NuVasive to $24,2011-09-22 07:32:00-04:00,NUVA,positive
927399.0,Afternoon Losers; AOL Down 12%,2011-09-21 15:50:00-04:00,NUVA,negative
927400.0,Rodman & Renshaw Outperform on NuVasive,2011-09-21 12:35:00-04:00,NUVA,neutral
927401.0,Jefferies Maintains Buy on NuVasive,2011-09-21 08:49:00-04:00,NUVA,neutral
927402.0,Benzinga's Top Pre-Market Losers,2011-09-21 08:26:00-04:00,NUVA,negative
927403.0,UPDATE: Piper Jaffray Lowers PT on NuVasive to $35,2011-09-21 07:37:00-04:00,NUVA,negative
927404.0,J.P. Morgan Neutral on NuVasive,2011-09-21 07:33:00-04:00,NUVA,neutral
927405.0,NuVasive Resumes Trading,2011-09-21 07:23:00-04:00,NUVA,neutral
927406.0,NuVasive Announces Jury Verdict in Patent Case  ,2011-09-21 06:52:00-04:00,NUVA,positive
927407.0,Piper Jaffray Lowers PT on NuVasive to $35,2011-09-21 06:02:00-04:00,NUVA,negative
927408.0,"Jury Finds That Medtronic and Nuvasive Infringed on Each Other's Patents; Awarded Medtronic $10.1M in Damages, Nuvasive $660K",2011-09-20 17:20:00-04:00,NUVA,negative
927409.0,Trading Halted on Nuvasive; News Pending,2011-09-20 17:07:00-04:00,NUVA,neutral
927410.0,Notable Call Options Activity in NuVasive,2011-09-16 15:20:00-04:00,NUVA,neutral
927411.0,UPDATE: Rodman & Renshaw Upgrades NuVasive from Market Perform to Market Outperform With a PT of $33,2011-08-15 10:06:00-04:00,NUVA,neutral
927412.0,"Rodman & Renshaw Upgrades NuVasive To Market Outperform, $33 PT",2011-08-15 08:23:00-04:00,NUVA,neutral
927413.0,Rodman & Renshaw Maintains NuVasive Market Perform,2011-07-26 15:38:00-04:00,NUVA,neutral
927414.0,UPDATE: Piper Jaffray Raises PT on NuVasive to $42,2011-07-26 08:46:00-04:00,NUVA,neutral
927415.0,Piper Jaffray Raises PT On NuVasive To $42,2011-07-26 07:31:00-04:00,NUVA,neutral
927416.0,UPDATE: JP Morgan Raises PT on NuVasive from $33 to $34,2011-07-26 06:44:00-04:00,NUVA,positive
927418.0,JP Morgan Raises PT On NuVasive To $34,2011-07-26 05:57:00-04:00,NUVA,positive
927419.0,NuVasive Cuts 2011 EPS Guidance to $1.09-$1.12 vs $1.21 Est,2011-07-25 16:47:00-04:00,NUVA,negative
927420.0,UPDATE: NuVasive Cuts Guidance for Year Adjusted EPS On Conv Note Placement,2011-07-25 16:45:00-04:00,NUVA,negative
927421.0,NuVasive Reports Q2 EPS of $0.30 vs. $0.29 Est; Revenues $133M vs. $132.04 M Est,2011-07-25 16:44:00-04:00,NUVA,neutral
927422.0,Earnings Scheduled For July 25,2011-07-25 04:42:00-04:00,NUVA,neutral
927423.0,"Zimmer Holdings Earnings Preview: Analyts Expect Flat Earnings, Revenue from Prior Quarter",2011-07-22 13:11:00-04:00,NUVA,neutral
927424.0,Fifteen Health Care ETFs Trading Near 52-Week Highs,2011-07-21 13:57:00-04:00,NUVA,positive
927425.0,Benzinga's Top Upgrades,2011-07-21 08:00:00-04:00,NUVA,positive
927426.0,BMO Capital Upgrades NuVasive to Outperform from Market Perform,2011-07-21 07:49:00-04:00,NUVA,neutral
927427.0,"Earnings Preview: Stryker EPS, Revenue Expected to Rise from Previous Quarter",2011-07-19 12:39:00-04:00,NUVA,neutral
927428.0,Robert W. Baird Upgrades NuVasive To Outperform,2011-07-19 08:19:00-04:00,NUVA,neutral
927429.0,Benzinga's Top Upgrades,2011-07-19 07:57:00-04:00,NUVA,positive
927430.0,Twelve Health Care ETFs Trading Near 52-Week Highs,2011-07-13 07:38:00-04:00,NUVA,positive
927431.0,Top 4 NASDAQ Stocks In The Medical Instruments & Supplies Industry With The Highest Profit Margin,2011-06-28 01:10:00-04:00,NUVA,positive
927432.0,U.S. Stocks Rebound From Lower Open,2011-06-22 10:25:00-04:00,NUVA,negative
927433.0,NuVasive to Offer $325 Million Convertible Senior Notes Due 2017,2011-06-21 16:17:00-04:00,NUVA,neutral
927434.0,"Bank of America Provides Color on NuVasive, Buy",2011-06-10 08:43:00-04:00,NUVA,neutral
927435.0,Top 4 Small-Cap Stocks In The Medical Instruments & Supplies Industry With The Lowest PEG Ratio,2011-06-08 01:41:00-04:00,NUVA,negative
927436.0,Bank of America Merrill Lynch Reiterates Buy on Nuvasive,2011-05-25 08:00:00-04:00,NUVA,neutral
927437.0,Jefferies Comments On NuVasive 1Q Results,2011-05-05 08:48:00-04:00,NUVA,neutral
927438.0,UPDATE: J.P. Morgan Color On NUVA Target Increase,2011-05-05 07:46:00-04:00,NUVA,positive
927439.0,JP Morgan Raises PT On NuVasive To $33,2011-05-05 06:17:00-04:00,NUVA,positive
927440.0,NuVasive Guides FY 2011 EPS $1.20-1.23 vs. $1.09 Estimate; Revenues $530-540M vs. $530.6M Est. (NUVA),2011-05-04 16:36:00-04:00,NUVA,neutral
927441.0,NuVasive Reports Revenues $124.5M vs. $123.14M Estimate (NUVA),2011-05-04 16:30:00-04:00,NUVA,neutral
927442.0,Piper Jaffray Reiterates Overweight Rating On NuVasive,2011-03-11 07:57:00-05:00,NUVA,negative
927443.0,J.P. Morgan To Adjust Ratings For NuVasive Following 4Q10 Results,2011-03-04 08:51:00-05:00,NUVA,neutral
927444.0,Piper Jaffray Comments On NuVasive Following Recent Earnings Report,2011-02-24 08:20:00-05:00,NUVA,neutral
927445.0,"NUVA 4Q Upside Encouraging But Visibility Remains Poor, J.P. Morgan Reports",2011-02-24 08:04:00-05:00,NUVA,negative
927446.0,Piper Jaffray Raises PT On NuVasive To $39,2011-02-24 07:13:00-05:00,NUVA,neutral
927447.0,NuVasive Reports Q4 EPS of $0.46 vs. $0.42; Revenue $129.3MM vs. $125.64M,2011-02-23 16:53:00-05:00,NUVA,neutral
927448.0,"Benzinga's Volume Movers (ADTN, NUVA, CHTR, PMTC)",2011-01-19 11:16:00-05:00,NUVA,neutral
927449.0,"Benzinga's Top Pre-Market NASDAQ Gainers (NUVA, HEV, ISPH, CVVT)",2011-01-19 08:36:00-05:00,NUVA,positive
927450.0,"Jefferies Remains Positive On NUVA, Lowers PT To $34 From $36",2011-01-11 09:12:00-05:00,NUVA,positive
927451.0,"NUVA Amends 2011 Outlook, J.P. Morgan Reports",2011-01-11 09:08:00-05:00,NUVA,neutral
927452.0,Jefferies Lowers PT On NuVasive,2011-01-11 07:09:00-05:00,NUVA,negative
927453.0,J.P Morgan Upgrades NuVasive To Neutral,2011-01-03 08:02:00-05:00,NUVA,neutral
927454.0,JP Morgan Ups NUVA To Neutral,2011-01-03 06:59:00-05:00,NUVA,positive
927455.0,JP Morgan Upgrades NuVasive To Neutral,2011-01-03 06:58:00-05:00,NUVA,positive
927456.0,"BTDStocks.com Friday, December 31, 2010 End-Of-Day Update",2010-12-31 21:43:00-05:00,NUVA,neutral
927457.0,"BTDStocks.com Thursday, December 30, 2010 End-Of-Day Update",2010-12-30 21:35:00-05:00,NUVA,neutral
927458.0,"BTDStocks.com Wednesday, December 29, 2010",2010-12-29 23:47:00-05:00,NUVA,neutral
927459.0,"BTDStocks.com Tuesday, December 28, 2010 End-Of-Day Update ",2010-12-28 20:59:00-05:00,NUVA,neutral
927460.0,"BTDStocks.com Monday, December 27, 2010 End-Of-Day Update",2010-12-27 21:31:00-05:00,NUVA,neutral
927461.0,"BTDStocks.com Thursday, December 23, 2010 End-Of-Day Update",2010-12-23 21:30:00-05:00,NUVA,neutral
927462.0,"BTDStocks.com Wednesday, December 22, 2010 End-Of-Day Update",2010-12-22 21:54:00-05:00,NUVA,neutral
927463.0,"BTDStocks.com Tuesday, December 21, 2010 End-Of-Day Update",2010-12-21 21:28:00-05:00,NUVA,neutral
927464.0,"BTDStocks.com Monday, December 20, 2010 End-Of-Day Update",2010-12-20 21:19:00-05:00,NUVA,neutral
927465.0,"BTDStocks.com Friday, December 17, 2010 End-Of-Day Update",2010-12-17 22:18:00-05:00,NUVA,neutral
927466.0,NuVasive Ends Friday Up 8.2% (NUVA),2010-12-17 16:44:00-05:00,NUVA,neutral
927467.0,"BTDStocks.com Thursday, December 16, 2010 End-Of-Day Update",2010-12-16 22:04:00-05:00,NUVA,neutral
927468.0,"BTDStocks.com Wednesday, December 15, 2010 End-Of-Day Update",2010-12-15 22:22:00-05:00,NUVA,neutral
927469.0,"BTDStocks.com Tuesday, December 14, 2010 End-Of-Day Update",2010-12-14 21:06:00-05:00,NUVA,neutral
927470.0,"BTDStocks.com Monday, December 13, 2010 End-Of-Day Update ",2010-12-13 22:13:00-05:00,NUVA,neutral
927471.0,"BTDStocks.com Friday, December 10, 2010 End-Of-Day Update",2010-12-11 10:49:00-05:00,NUVA,neutral
927472.0,"BTDStocks.com Thursday, December 9, 2010 End-Of-Day Update",2010-12-09 22:20:00-05:00,NUVA,neutral
927473.0,"BTDStocks.com Tuesday, December 7, 2010 End-Of-Day Update",2010-12-07 21:09:00-05:00,NUVA,neutral
927474.0,"BTDStocks.com Monday, December 6, 2010 End-Of-Day Update",2010-12-07 00:08:00-05:00,NUVA,neutral
927475.0,"BTDStocks.com Friday, December 3, 2010 End-Of-Day Update",2010-12-03 22:10:00-05:00,NUVA,neutral
927476.0,"BTDStocks.com Thursday, December 2, 2010 End-Of-Update",2010-12-02 21:24:00-05:00,NUVA,neutral
927477.0,"BTDStocks.com Wednesday, December 1, 2010 End-Of-Day Update ",2010-12-01 21:35:00-05:00,NUVA,neutral
927478.0,"BTDStocks.com Tuesday, November 30, 2010 End-Of-Day Update",2010-11-30 21:28:00-05:00,NUVA,neutral
927479.0,3 Stocks That Should Rally Nicely in 2011,2010-11-29 08:00:00-05:00,NUVA,positive
927480.0,"BTDStocks.com Friday, November 26, 2010 End-Of-Day Update",2010-11-27 11:03:00-05:00,NUVA,neutral
927481.0,"BTDStocks.com Wednesday, November 24, 2010 End-Of-Day Update",2010-11-24 22:35:00-05:00,NUVA,neutral
927482.0,"BTDStocks.com Tuesday, November 23, 2010 End-Of-Day Update",2010-11-23 20:56:00-05:00,NUVA,neutral
927483.0,"BTDStocks.com Monday, November 15, 2010 End-Of-Day Update",2010-11-15 21:31:00-05:00,NUVA,neutral
927484.0,NuVasive Down After Earnings Miss (NUVA),2010-10-29 15:35:00-04:00,NUVA,negative
927485.0,NuVasive Falls To 52-Week Low (NUVA),2010-10-29 10:49:00-04:00,NUVA,negative
927486.0,"J.P. Morgan Lowers Estimates, Downgrades NuVasive Rating",2010-10-29 09:35:00-04:00,NUVA,negative
927487.0,"Benzinga's Top Pre-Market NASDAQ Losers (NUVA, AMAG, FSLR, CRXL)",2010-10-29 08:40:00-04:00,NUVA,negative
927488.0,"Benzinga's After Hours Decliners (FSLR, APKT, NUVA, AMAG, CLF, GNW)",2010-10-28 19:44:00-04:00,NUVA,neutral
927489.0,Goldman Sachs Raises EPS Estimates On NuVasive,2010-10-05 07:10:00-04:00,NUVA,neutral
927490.0,Piper Jaffray Reiterates Overweight Rating On NuVasive (NUVA),2010-09-15 14:28:00-04:00,NUVA,negative
927491.0,NuVasive Hosts Analyst Meeting,2010-09-15 10:22:00-04:00,NUVA,neutral
927492.0,Jefferies Lowers Price Target On NuVasive (NUVA),2010-09-15 07:16:00-04:00,NUVA,negative
927493.0,"Benzinga's Volume Movers (NUVA, ASMI, ZUMZ, SSRI)",2010-09-14 13:06:00-04:00,NUVA,neutral
927494.0,"Benzinga's Top Pre-Market NASDAQ Losers (ARMH, NUVA, ARNA, THQI)",2010-09-14 09:26:00-04:00,NUVA,negative
927495.0,NuVasive Poised For Strong Results,2010-09-07 08:32:00-04:00,NUVA,positive
927496.0,NUVA’s Management Remains Confident In Its Ability To Achieve 2010 And 2011 Growth Goals,2010-08-13 13:25:00-04:00,NUVA,positive
927497.0,Piper Jaffray Reiterates Overweight Rating on NuVasive (NUVA),2010-07-28 15:12:00-04:00,NUVA,negative
927498.0,"Stocks Falling On Unusual Volume (NUVA, MANT)",2010-07-20 13:31:00-04:00,NUVA,negative
927499.0,NuVasive ( NUVA) Gets Buy Rating  ,2010-06-17 20:52:00-04:00,NUVA,neutral
927500.0,NuVasive to Present at the Goldman Sachs Healthcare Conference and the William Blair Growth Stock Conference (NUVA),2010-06-03 16:35:00-04:00,NUVA,positive
927501.0,Needham Bullish On NuVasive (NUVA),2010-04-21 09:24:00-04:00,NUVA,neutral
927502.0,Needham Rates NuVasive A Strong Buy (NUVA),2010-04-19 12:51:00-04:00,NUVA,positive
927503.0,"NuVasive, Inc.’s (NUVA) Fourth-Quarter Review",2010-02-26 17:35:00-05:00,NUVA,neutral
927504.0,"PiperJaffray Lowers NuVasive (NUVA) Price Target, Reiterates Overweight Rating",2010-02-26 09:56:00-05:00,NUVA,negative
927505.0,NuVasive (NUVA) Maintains Its Rating From Barclays,2010-02-02 13:32:00-05:00,NUVA,neutral
927506.0,Genentech Inc. (DNA) Faces A Double Whammy – CNBC,2010-02-02 13:29:00-05:00,NUVA,neutral
927507.0,Jefferies Initiates Coverage Of NuVasive With A Buy (NUVA),2010-01-22 15:01:00-05:00,NUVA,neutral
927508.0,NUVA’s Business Momentum Remains Intact,2009-12-01 12:48:00-05:00,NUVA,positive
927509.0,NuVasive: Concerns Over Reimbursement Overblown,2009-12-01 12:00:00-05:00,NUVA,neutral
927510.0,"Benzinga’s Top Downgrades (CHD, NUVA, NFLX)",2009-12-01 10:37:00-05:00,NUVA,positive
927511.0,"Benzinga’s Top Pre- Market Losers (LTON, OVTI, LINC, NLST, HGSI, NUVA, AFFX)",2009-12-01 09:04:00-05:00,NUVA,negative
927512.0,"Benzinga's Volume Movers (APWR, HAYN, BCSI, NUVA)",2009-11-25 14:12:00-05:00,NUVA,neutral
